Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TKM-Marburg
- Development stage
- Preclinical
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TKM-Marburg is an experimental therapeutic developed to treat Marburg virus infection, a highly fatal hemorrhagic fever caused by the Marburg virus. It consists of small interfering RNAs (siRNAs) encapsulated in lipid nanoparticles (LNPs). These siRNAs are designed to block the expression of Marburg viral genes, thereby inhibiting viral replication within host cells. The formulation was shown to rescue nonhuman primates from lethal Marburg virus infection, even when administration began as late as three days after exposure. It was originally developed by Tekmira Pharmaceuticals (now known as Arbutus Biopharma) as part of antiviral countermeasures against filoviruses like Ebola and Marburg[2][4][16][13].
- Brand names
- TKM-Marburg
- Other names
- NP-718m-LNPNP718m-LNPNP 718m-LNP
02
Targets
MARV RNA (Marburg virus genomic RNA)
Beyond the preview
Go deeper on TKM-Marburg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TKM-Marburg.